Wockhardt recorded a consolidated net loss of Rs92.79cr in the quarter ended March 2021 as against a net profit of Rs48.29cr during the previous quarter ended March 2020.
The revenue declined 8% to Rs631.96cr in the quarter ended March 2021 as against Rs686.93cr during the previous quarter ended March 2020.
Wockhardt Ltd ended at Rs675 down by Rs110.95 or 14.12% from its previous closing of Rs785.95 on the BSE.
UK Business during the quarter stood at Rs261crore in Q4FY21 (PY Rs.229 crore) showing a growth of 14%. UK Business contributed about 41% of Global Revenue. Major growth has come from the COVID-19 Vaccine business ~5mn GBP.
Emerging Markets Business of the Company stood at Rs121cr in Q4FY21 (PY Rs133cr). Emerging Markets Business contributed about 19% of the Global Revenue.
India Business (both Continued and Discontinued Operations) stood at Rs118cr in Q4FY21 as compared to Rs177cr in Q4FY20. The Continuing Business stood at Rs120 in Q4FY21 (PY Rs74cr) registering a growth of 63%. India Business contributed 19% of the Global Revenue.
Irish Business stood at Rs32cr in Q4FY21 (PY Rs38cr).
US Business stood at Rs95cr in Q4FY21 as compared to Rs189cr in Q4FY20. US Business contributed 15% of the Global Revenue.
Research and Development expenditure during the quarter was at Rs48cr (8% to sales) and including capital expenditure was at 11% to sales. Capital expenditure during the quarter was Rs22cr.
Wockhardt Ltd ended at Rs675, down by Rs110.95 or 14.12% from its previous closing of Rs785.95 on the BSE.
#Wockhardt #reports #consolidated #net #loss #Rs9279cr
( With inputs from indiainfoline)